Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Long Agonist Protocol

Clinical and Live Birth Rates After Controlled Ovarian Stimulation With the Long Antagonist Protocol Versus the Long Agonist Protocol

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03693534

Enrollment

120

Registered

2018-10-03

Start date

2017-02-15

Completion date

2021-06-30

Last updated

2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy, Ovarian

Keywords

Long Antagonist, Long agonist, clinical pregnancy rate, live birth rate, ovarian stimulation, IVF

Brief summary

A prospective study of the evaluation of the clinical IVF (in vitro fertilization) results after following Long Antagonist protocol for Controlled Ovarian Stimulation (COS) versus following Long Agonist protocol

Detailed description

A prospective study of the clinical results in women who followed the Long Antagonist protocol for Controlled Ovarian Stimulation (COS) versus women who followed Long Agonist protocol, in an In Vitro Fertilization (IVF) try. In particular, the Clinical Pregnancy Rates (CPR) and Live Birth Rates (LBR) were estimated for the two groups of patients. The number of the formed blastocysts was also measured in each group of patients.

Interventions

DIAGNOSTIC_TESTClinical Pregnancy Rate

The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 39 Years

Healthy volunteers

Yes

Inclusion criteria

* primary infertility * age 18-39 years; body mass index (BMI) 18-29kg/m2; * regular menstrual cycle of 26-35days, * presumed to be ovulatory; * early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).

Exclusion criteria

* women with diabetes and other metabolic disease * women with heart disease, QT prolongation,heart failure * elevated liver enzymes, liver failure, hepatitis * women with inflammatory or autoimmune disease * abnormal karyotype; * polycystic ovarian syndrome, * endometriosis stage III/IV; * history of being a 'poor responder', * defined as \>20 days of gonadotrophin in a previous stimulation cycle, or any previous cancellation of a stimulation cycle due to limited follicular response, or development of less than 4 follicles 15 mm in a previous stimulation cycle; history of recurrent miscarriage; severe OHSS in a previous stimula- tion cycle or any contraindication for the use of gonadotrophins.

Design outcomes

Primary

Measure	Time frame	Description
Clinical Pregnancy Rate according to stimulation protocol	6 weeks to 42 weeks after embryo transfer	Clinical Pregnancy Rate according to stimulation protocol
Number of formed blastocysts in each group of patients	5 days after the OPU day	The number of the formed blastocysts in each group of patients according to the COS protocol

Secondary

Measure	Time frame	Description
Live Birth Rate according to stimulation protocol	6 weeks to 42 weeks after embryo transfer	Live Birth Rate according to stimulation protocol

Countries

Greece

Contacts

Primary ContactEvaggelos Papanikolaou, MD,PhD

drvagpapanikolaou@yahoo.gr00302310424294

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026